172 related articles for article (PubMed ID: 16314831)
1. Suppression of KCMF1 by constitutive high CD99 expression is involved in the migratory ability of Ewing's sarcoma cells.
Kreppel M; Aryee DN; Schaefer KL; Amann G; Kofler R; Poremba C; Kovar H
Oncogene; 2006 May; 25(19):2795-800. PubMed ID: 16314831
[TBL] [Abstract][Full Text] [Related]
2. Notch signalling is off and is uncoupled from HES1 expression in Ewing's sarcoma.
Bennani-Baiti IM; Aryee DN; Ban J; Machado I; Kauer M; Mühlbacher K; Amann G; Llombart-Bosch A; Kovar H
J Pathol; 2011 Nov; 225(3):353-63. PubMed ID: 21984123
[TBL] [Abstract][Full Text] [Related]
3. Caveolin-1 (CAV1) is a target of EWS/FLI-1 and a key determinant of the oncogenic phenotype and tumorigenicity of Ewing's sarcoma cells.
Tirado OM; Mateo-Lozano S; Villar J; Dettin LE; Llort A; Gallego S; Ban J; Kovar H; Notario V
Cancer Res; 2006 Oct; 66(20):9937-47. PubMed ID: 17047056
[TBL] [Abstract][Full Text] [Related]
4. EWS-FLI-1 expression triggers a Ewing's sarcoma initiation program in primary human mesenchymal stem cells.
Riggi N; Suvà ML; Suvà D; Cironi L; Provero P; Tercier S; Joseph JM; Stehle JC; Baumer K; Kindler V; Stamenkovic I
Cancer Res; 2008 Apr; 68(7):2176-85. PubMed ID: 18381423
[TBL] [Abstract][Full Text] [Related]
5. CD99 engagement: an effective therapeutic strategy for Ewing tumors.
Scotlandi K; Baldini N; Cerisano V; Manara MC; Benini S; Serra M; Lollini PL; Nanni P; Nicoletti G; Bernard G; Bernard A; Picci P
Cancer Res; 2000 Sep; 60(18):5134-42. PubMed ID: 11016640
[TBL] [Abstract][Full Text] [Related]
6. Primary Ewing's sarcoma family tumors of the lung a case report and review of the literature.
Takahashi D; Nagayama J; Nagatoshi Y; Inagaki J; Nishiyama K; Yokoyama R; Moriyasu Y; Okada K; Okamura J
Jpn J Clin Oncol; 2007 Nov; 37(11):874-7. PubMed ID: 17998263
[TBL] [Abstract][Full Text] [Related]
7. Beta-platelet-derived growth factor receptor mediates motility and growth of Ewing's sarcoma cells.
Uren A; Merchant MS; Sun CJ; Vitolo MI; Sun Y; Tsokos M; Illei PB; Ladanyi M; Passaniti A; Mackall C; Toretsky JA
Oncogene; 2003 Apr; 22(15):2334-42. PubMed ID: 12700668
[TBL] [Abstract][Full Text] [Related]
8. Engagement of CD99 induces apoptosis through a calcineurin-independent pathway in Ewing's sarcoma cells.
Sohn HW; Choi EY; Kim SH; Lee IS; Chung DH; Sung UA; Hwang DH; Cho SS; Jun BH; Jang JJ; Chi JG; Park SH
Am J Pathol; 1998 Dec; 153(6):1937-45. PubMed ID: 9846983
[TBL] [Abstract][Full Text] [Related]
9. siRNA associated with immunonanoparticles directed against cd99 antigen improves gene expression inhibition in vivo in Ewing's sarcoma.
Ramon AL; Bertrand JR; de Martimprey H; Bernard G; Ponchel G; Malvy C; Vauthier C
J Mol Recognit; 2013 Jul; 26(7):318-29. PubMed ID: 23657987
[TBL] [Abstract][Full Text] [Related]
10. Caveolin-1 modulates the ability of Ewing's sarcoma to metastasize.
Sáinz-Jaspeado M; Lagares-Tena L; Lasheras J; Navid F; Rodriguez-Galindo C; Mateo-Lozano S; Notario V; Sanjuan X; Garcia Del Muro X; Fabra A; Tirado OM
Mol Cancer Res; 2010 Nov; 8(11):1489-500. PubMed ID: 21106507
[TBL] [Abstract][Full Text] [Related]
11. BMI-1 promotes ewing sarcoma tumorigenicity independent of CDKN2A repression.
Douglas D; Hsu JH; Hung L; Cooper A; Abdueva D; van Doorninck J; Peng G; Shimada H; Triche TJ; Lawlor ER
Cancer Res; 2008 Aug; 68(16):6507-15. PubMed ID: 18701473
[TBL] [Abstract][Full Text] [Related]
12. CD99 triggering in Ewing sarcoma delivers a lethal signal through p53 pathway reactivation and cooperates with doxorubicin.
Guerzoni C; Fiori V; Terracciano M; Manara MC; Moricoli D; Pasello M; Sciandra M; Nicoletti G; Gellini M; Dominici S; Chiodoni C; Fornasari PM; Lollini PL; Colombo MP; Picci P; Cianfriglia M; Magnani M; Scotlandi K
Clin Cancer Res; 2015 Jan; 21(1):146-56. PubMed ID: 25501132
[TBL] [Abstract][Full Text] [Related]
13. STAT3 is activated in a subset of the Ewing sarcoma family of tumours.
Lai R; Navid F; Rodriguez-Galindo C; Liu T; Fuller CE; Ganti R; Dien J; Dalton J; Billups C; Khoury JD
J Pathol; 2006 Apr; 208(5):624-32. PubMed ID: 16463269
[TBL] [Abstract][Full Text] [Related]
14. DAX1, a direct target of EWS/FLI1 oncoprotein, is a principal regulator of cell-cycle progression in Ewing's tumor cells.
García-Aragoncillo E; Carrillo J; Lalli E; Agra N; Gómez-López G; Pestaña A; Alonso J
Oncogene; 2008 Oct; 27(46):6034-43. PubMed ID: 18591936
[TBL] [Abstract][Full Text] [Related]
15. CD99 inhibits neural differentiation of human Ewing sarcoma cells and thereby contributes to oncogenesis.
Rocchi A; Manara MC; Sciandra M; Zambelli D; Nardi F; Nicoletti G; Garofalo C; Meschini S; Astolfi A; Colombo MP; Lessnick SL; Picci P; Scotlandi K
J Clin Invest; 2010 Mar; 120(3):668-80. PubMed ID: 20197622
[TBL] [Abstract][Full Text] [Related]
16. Ewing's sarcoma metastasis to the gastric wall in a 72-year-old patient.
Dodis LB; Bennett MW; Carr-Locke DL
MedGenMed; 2006 Jul; 8(3):6. PubMed ID: 17406148
[No Abstract] [Full Text] [Related]
17. The sensitivity of the Ewing's sarcoma family of tumours to fenretinide-induced cell death is increased by EWS-Fli1-dependent modulation of p38(MAPK) activity.
Myatt SS; Burchill SA
Oncogene; 2008 Feb; 27(7):985-96. PubMed ID: 17700534
[TBL] [Abstract][Full Text] [Related]
18. Differentiating lymphoblastic lymphoma and Ewing's sarcoma: lymphocyte markers and gene rearrangement.
Ozdemirli M; Fanburg-Smith JC; Hartmann DP; Azumi N; Miettinen M
Mod Pathol; 2001 Nov; 14(11):1175-82. PubMed ID: 11706081
[TBL] [Abstract][Full Text] [Related]
19. NR0B1 is required for the oncogenic phenotype mediated by EWS/FLI in Ewing's sarcoma.
Kinsey M; Smith R; Lessnick SL
Mol Cancer Res; 2006 Nov; 4(11):851-9. PubMed ID: 17114343
[TBL] [Abstract][Full Text] [Related]
20. Targeting CD99 in association with doxorubicin: an effective combined treatment for Ewing's sarcoma.
Scotlandi K; Perdichizzi S; Bernard G; Nicoletti G; Nanni P; Lollini PL; Curti A; Manara MC; Benini S; Bernard A; Picci P
Eur J Cancer; 2006 Jan; 42(1):91-6. PubMed ID: 16326096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
